Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Hikma Pharmaceuticals ( (GB:HIK) ) has shared an update.
Hikma Pharmaceuticals PLC has reported that, as of 28 February 2026, its issued share capital consists of 221,606,453 ordinary shares of 10 pence each with voting rights, excluding 12,833,233 shares held in treasury that carry no voting rights. This updated share count serves as the reference denominator for shareholders and other market participants when calculating whether they must disclose holdings or changes in their interests under UK transparency rules.
The most recent analyst rating on (GB:HIK) stock is a Sell with a £13.50 price target. To see the full list of analyst forecasts on Hikma Pharmaceuticals stock, see the GB:HIK Stock Forecast page.
Spark’s Take on GB:HIK Stock
According to Spark, TipRanks’ AI Analyst, GB:HIK is a Neutral.
The score is held back primarily by weakening cash generation and a notably bearish technical trend (oversold and trading below key moving averages). These are partially offset by attractive valuation (low P/E and strong dividend yield) and a constructive earnings-call outlook supported by guidance comfort and a GBP 250m buyback, despite near-term injectable headwinds.
To see Spark’s full report on GB:HIK stock, click here.
More about Hikma Pharmaceuticals
Hikma Pharmaceuticals PLC is a London-listed pharmaceutical company operating in the healthcare sector. It focuses on developing, manufacturing, and marketing a broad range of generic and branded medicines for global markets, with a particular emphasis on injectable and oral pharmaceuticals used in hospitals and retail pharmacies.
Average Trading Volume: 1,010,435
Technical Sentiment Signal: Sell
Current Market Cap: £3.06B
For a thorough assessment of HIK stock, go to TipRanks’ Stock Analysis page.